CY2019037I2 - Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων - Google Patents

Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων

Info

Publication number
CY2019037I2
CY2019037I2 CY2019037C CY2019037C CY2019037I2 CY 2019037 I2 CY2019037 I2 CY 2019037I2 CY 2019037 C CY2019037 C CY 2019037C CY 2019037 C CY2019037 C CY 2019037C CY 2019037 I2 CY2019037 I2 CY 2019037I2
Authority
CY
Cyprus
Prior art keywords
corticosteroids
plus
chemotherapy
tumor treatment
plus non
Prior art date
Application number
CY2019037C
Other languages
English (en)
Other versions
CY2019037I1 (el
Original Assignee
Genmab A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2019037(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genmab A/S filed Critical Genmab A/S
Publication of CY2019037I1 publication Critical patent/CY2019037I1/el
Publication of CY2019037I2 publication Critical patent/CY2019037I2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CY2019037C 2006-09-26 2019-10-10 Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων CY2019037I2 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84732906P 2006-09-26 2006-09-26
DKPA200601232 2006-09-26
PCT/DK2007/000418 WO2008037257A2 (en) 2006-09-26 2007-09-26 Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors

Publications (2)

Publication Number Publication Date
CY2019037I1 CY2019037I1 (el) 2020-05-29
CY2019037I2 true CY2019037I2 (el) 2020-05-29

Family

ID=39156080

Family Applications (8)

Application Number Title Priority Date Filing Date
CY20191100718T CY1121813T1 (el) 2006-09-26 2019-07-09 Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
CY2019036C CY2019036I2 (el) 2006-09-26 2019-10-10 Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
CY2019037C CY2019037I2 (el) 2006-09-26 2019-10-10 Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
CY2019035C CY2019035I1 (el) 2006-09-26 2019-10-10 Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
CY2020016C CY2020016I2 (el) 2006-09-26 2020-07-03 Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
CY2021038C CY2021038I2 (el) 2006-09-26 2021-12-20 Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
CY2021037C CY2021037I1 (el) 2006-09-26 2021-12-20 Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
CY2025011C CY2025011I2 (el) 2006-09-26 2025-04-16 Anti-cd38 συν κορτικοστεροειδη συν μη- κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20191100718T CY1121813T1 (el) 2006-09-26 2019-07-09 Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
CY2019036C CY2019036I2 (el) 2006-09-26 2019-10-10 Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων

Family Applications After (5)

Application Number Title Priority Date Filing Date
CY2019035C CY2019035I1 (el) 2006-09-26 2019-10-10 Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
CY2020016C CY2020016I2 (el) 2006-09-26 2020-07-03 Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
CY2021038C CY2021038I2 (el) 2006-09-26 2021-12-20 Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
CY2021037C CY2021037I1 (el) 2006-09-26 2021-12-20 Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
CY2025011C CY2025011I2 (el) 2006-09-26 2025-04-16 Anti-cd38 συν κορτικοστεροειδη συν μη- κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων

Country Status (24)

Country Link
US (4) US9040050B2 (el)
EP (3) EP3569245A1 (el)
JP (7) JP5476122B2 (el)
AU (2) AU2007302448C1 (el)
CA (1) CA2664740C (el)
CY (8) CY1121813T1 (el)
DK (1) DK2081595T3 (el)
EA (1) EA034877B1 (el)
ES (1) ES2732278T3 (el)
FI (1) FIC20250018I1 (el)
FR (7) FR19C1056I1 (el)
HR (1) HRP20191115T1 (el)
HU (7) HUE044136T2 (el)
IL (2) IL197727A (el)
LT (8) LT2081595T (el)
LU (3) LUC00129I2 (el)
ME (1) ME03503B (el)
NZ (1) NZ576122A (el)
PL (1) PL2081595T3 (el)
PT (1) PT2081595T (el)
RS (1) RS59005B1 (el)
SI (1) SI2081595T1 (el)
TR (1) TR201910145T4 (el)
WO (1) WO2008037257A2 (el)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567976B1 (en) * 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP3569245A1 (en) * 2006-09-26 2019-11-20 Genmab A/S Combination treatment of cd38-expressing tumors
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191841A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
WO2011050180A1 (en) * 2009-10-21 2011-04-28 Immunogen, Inc. Novel dosing regimen and method of treatment
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
SI2621531T1 (sl) 2010-09-27 2017-06-30 Morphosys Ag Anti-cd38 protitelo in lenalidomid ali bortezomib za zdravljenje multiplega mieloma in nhl
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
PT2707030T (pt) 2011-05-09 2020-05-22 Mayo Found Medical Education & Res Tratamentos de cancro
SG10201603411WA (en) 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
JP6426093B2 (ja) 2012-09-25 2018-11-28 モルフォシス・アーゲー 組み合わせ及びその使用
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
JP6279065B2 (ja) * 2013-03-13 2018-02-14 サノフイ 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
ES2774976T3 (es) * 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
SG10201803288RA (en) * 2013-10-31 2018-05-30 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US20160250351A1 (en) 2014-06-13 2016-09-01 Mayo Foundation For Medical Education And Research Treating Lymphomas
EP3834889A1 (en) * 2014-06-16 2021-06-16 Mayo Foundation for Medical Education and Research Treating myelomas
US10617757B2 (en) * 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
MX386886B (es) 2014-09-09 2025-03-12 Janssen Biotech Inc Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
CA2965414C (en) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
AU2015358615B2 (en) * 2014-12-04 2021-08-05 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
PT3294769T (pt) 2015-05-13 2021-04-13 Morphosys Ag Tratamento para mieloma múltiplo (mm)
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
AU2016278040B2 (en) 2015-06-16 2019-07-04 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
AU2016282674B2 (en) * 2015-06-22 2022-01-13 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
HRP20240338T1 (hr) * 2015-06-24 2024-05-24 Janssen Biotech, Inc. Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
US11305020B2 (en) 2016-03-21 2022-04-19 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
CA3035377A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Nanoparticle compositions for targeting t-cell cancers
CN109890419A (zh) 2016-09-01 2019-06-14 梅约医学教育与研究基金会 用于治疗癌症的载体-pd-l1结合剂组合物
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
EP3509643A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
WO2018048816A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Methods of treating pd-l1 expressing cancer
JP7516047B2 (ja) * 2016-11-23 2024-07-16 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法
EP3581190B1 (en) 2016-12-09 2021-03-10 ONK Therapeutics Limited Engineered natural killer cells and uses thereof
KR102631281B1 (ko) * 2017-08-10 2024-01-30 그리폴스 다이어그노스틱 솔루션즈 인크. 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
KR20210006321A (ko) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
JP6648171B2 (ja) * 2018-02-02 2020-02-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
US12012461B2 (en) 2018-05-16 2024-06-18 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
MA53122A (fr) 2018-07-13 2021-05-19 Genmab As Variants d'anticorps cd38 et leurs utilisations
JP7534281B2 (ja) 2018-07-13 2024-08-14 ジェンマブ エー／エス Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療
US20200109394A1 (en) * 2018-10-03 2020-04-09 Prescient Pharma Llc Compositions and methods for isolating circulating cells
EP3938394A1 (en) 2019-03-15 2022-01-19 MorphoSys AG Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
CN113993543B (zh) 2019-06-10 2024-07-12 武田药品工业株式会社 使用抗cd38抗体的组合疗法
GB201916150D0 (en) 2019-11-06 2019-12-18 Univ Of Ireland Galway Treatment of multiple myeloma
CN112876563B (zh) 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
JP6853392B2 (ja) * 2020-01-15 2021-03-31 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
KR20220130724A (ko) 2020-01-16 2022-09-27 젠맵 에이/에스 Cd38 항체의 제제 및 그의 용도
IL295896A (en) 2020-02-26 2022-10-01 Biograph 55 Inc c19 c38 bispecific antibodies
WO2021226584A1 (en) * 2020-05-08 2021-11-11 University Of Southern California Site-specific antibody-drug conjugates by adp-ribosyl cyclases
KR20230079074A (ko) * 2020-09-01 2023-06-05 더 리전츠 오브 더 유니버시티 오브 캘리포니아 면역글로불린 ｅ 항체 조성물 및 사용 방법
WO2022152823A1 (en) 2021-01-14 2022-07-21 Morphosys Ag Anti-cd38 antibodies and their uses
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
US20250382378A1 (en) 2022-10-31 2025-12-18 Genmab A/S Cd38 antibodies and uses thereof
JP2026510999A (ja) 2023-03-21 2026-04-10 バイオグラフ ５５，インク． Ｃｄ１９／ｃｄ３８多重特異性抗体

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
HUT53672A (en) 1988-02-25 1990-11-28 Gen Hospital Corp Quick immunoselective cloning process
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
KR100206524B1 (ko) 1990-07-13 1999-07-01 어니스트 엠. 해데드 씨디 53 세포 표면 항원 및 그를 암호화하는 재조합 디엔에이
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
WO1994017184A1 (en) 1993-01-29 1994-08-04 Schering Corporation Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
DE69424687T2 (de) 1993-03-09 2000-09-07 Genzyme Corp., Cambridge Verfahren zur isolierung von proteinen aus milch
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
WO1998016245A1 (fr) 1996-10-15 1998-04-23 Shionogi & Co., Ltd. Procede de determination d'un auto-anticorps
WO1998016254A1 (en) 1996-10-17 1998-04-23 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
WO2000006194A2 (en) 1997-02-05 2000-02-10 Biotransplant, Inc. Depletion of cells responsible for antibody-mediated graft rejection
ES2248898T3 (es) 1997-05-02 2006-03-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Inmunotoxinas que comprenden una proteina onc dirigida contra celulas malignas.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6719977B1 (en) 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
CA2347067C (en) 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
WO1999062526A2 (en) * 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
CA2340091C (en) * 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
US20050037969A1 (en) 1999-05-14 2005-02-17 Arbor Vita Corporation Molecular interactions in hematopoietic cells
DE60037896D1 (de) 1999-07-29 2008-03-13 Medarex Inc Menschliche antikörper gegen her2/neu
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US6955884B2 (en) 2000-10-17 2005-10-18 Trudeau Institute, Inc. Methods for identifying compounds that inhibit CD38 activity
US20070042436A1 (en) 2000-10-17 2007-02-22 Lund Frances E CD38 modulated chemotaxis
WO2002042468A2 (en) 2000-11-27 2002-05-30 Geron Corporation Glycosyltransferase vectors for treating cancer
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
NZ530212A (en) 2001-06-13 2006-09-29 Genmab As An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR)
US20040166490A1 (en) 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20040019915A1 (en) 2002-04-01 2004-01-29 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
EP1393720A1 (en) 2002-08-27 2004-03-03 Universiteit Utrecht Vesicle-encapsulated corticosteroids for treatment of cancer
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
US7282568B2 (en) 2002-12-16 2007-10-16 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (IL-8)
EP2216342B1 (en) * 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
EP1689435A4 (en) 2003-10-22 2007-10-03 Univ Rochester ANTI-THYMOCYTE ANTISERUM AND ITS USE FOR TRIGGERING B-CELL APOPTOSIS
CA2544951A1 (en) * 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
WO2005046593A2 (en) * 2003-11-06 2005-05-26 Celgene Corporation Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
DK2511297T3 (en) * 2004-02-06 2015-06-15 Morphosys Ag Human anti-CD38 antibodies and their applications
US8263746B2 (en) * 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
US20050266008A1 (en) 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies
WO2005103803A1 (ja) * 2004-04-21 2005-11-03 Dai Nippon Printing Co., Ltd. カラーフィルター及びそれを備えた液晶表示装置
US20060019303A1 (en) 2004-07-23 2006-01-26 Boehringer Ingelheim Pharmaceuticals, Inc. Method to identify and analyze genes having modified expression in stimulated T cells
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
EP3569245A1 (en) * 2006-09-26 2019-11-20 Genmab A/S Combination treatment of cd38-expressing tumors
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma

Also Published As

Publication number Publication date
US20100092489A1 (en) 2010-04-15
JP2016188228A (ja) 2016-11-04
CY2019036I1 (el) 2020-05-29
JP2010504363A (ja) 2010-02-12
HUE044136T2 (hu) 2019-09-30
AU2007302448A1 (en) 2008-04-03
RS59005B1 (sr) 2019-08-30
JP5476122B2 (ja) 2014-04-23
LTPA2025516I1 (el) 2025-05-12
HUS1900045I1 (hu) 2019-11-28
JP2019001804A (ja) 2019-01-10
JP6607825B2 (ja) 2019-11-20
CY2020016I1 (el) 2020-11-25
HUS2100057I1 (hu) 2022-01-28
CY2019036I2 (el) 2020-05-29
FR25C1015I1 (fr) 2025-06-20
FR21C1062I1 (fr) 2022-02-18
CA2664740A1 (en) 2008-04-03
TR201910145T4 (tr) 2019-08-21
CY2019035I2 (el) 2020-05-29
EP2081595B1 (en) 2019-04-10
LTPA2021014I1 (el) 2022-01-10
AU2007302448B2 (en) 2013-12-19
CY2020016I2 (el) 2020-11-25
US20200114000A1 (en) 2020-04-16
CY2021037I2 (el) 2022-03-24
FR19C1057I1 (fr) 2019-11-15
JP2014141492A (ja) 2014-08-07
SI2081595T1 (sl) 2019-10-30
AU2013203186C1 (en) 2019-02-14
CY1121813T1 (el) 2020-05-29
CY2025011I1 (el) 2026-02-25
CY2019037I1 (el) 2020-05-29
US20150231235A1 (en) 2015-08-20
EP2081595A2 (en) 2009-07-29
CY2019035I1 (el) 2020-05-29
LUC00130I2 (el) 2024-05-22
JP2021119198A (ja) 2021-08-12
IL197727A (en) 2017-01-31
US9040050B2 (en) 2015-05-26
FR21C1063I1 (fr) 2022-02-18
JP6907165B2 (ja) 2021-07-21
CY2025011I2 (el) 2026-02-25
LTPA2019515I1 (lt) 2019-10-25
ES2732278T3 (es) 2019-11-21
CA2664740C (en) 2021-11-16
WO2008037257A2 (en) 2008-04-03
LTPA2020520I1 (lt) 2020-07-27
EP3569245A1 (en) 2019-11-20
HUS1900043I1 (hu) 2019-11-28
CY2021038I1 (el) 2022-03-24
US20240165226A1 (en) 2024-05-23
IL197727A0 (en) 2011-08-01
HUS2500018I1 (hu) 2025-05-28
FR20C1034I1 (fr) 2020-10-02
CY2021037I1 (el) 2022-03-24
HRP20191115T1 (hr) 2019-09-20
PT2081595T (pt) 2019-07-16
AU2007302448C1 (en) 2019-02-14
FR19C1056I1 (fr) 2019-11-15
AU2013203186A1 (en) 2013-05-02
WO2008037257A3 (en) 2008-06-05
EP3753576A1 (en) 2020-12-23
FIC20250018I1 (fi) 2025-04-17
PL2081595T3 (pl) 2019-11-29
LT2081595T (lt) 2019-07-10
CY2021038I2 (el) 2023-11-15
LUC00129I2 (el) 2024-05-22
LUC00128I2 (el) 2024-05-22
NZ576122A (en) 2012-09-28
IL248204A0 (en) 2016-11-30
JP2025143484A (ja) 2025-10-01
EA034877B1 (ru) 2020-04-01
FR19C1055I1 (fr) 2019-11-15
HUS2100056I1 (hu) 2022-01-28
LTPA2021015I1 (el) 2022-01-25
AU2013203186B2 (en) 2016-06-16
DK2081595T3 (da) 2019-07-15
LTPA2019514I1 (lt) 2025-12-29
ME03503B (me) 2020-04-20
LTPA2019516I1 (lt) 2019-10-25
EA200970317A1 (ru) 2009-10-30
HUS1900044I1 (hu) 2019-11-28
JP2023120436A (ja) 2023-08-29

Similar Documents

Publication Publication Date Title
CY2025011I1 (el) Anti-cd38 συν κορτικοστεροειδη συν μη- κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
LTC2076540I2 (lt) Nauji anti-cd38 antikūnai, skirti vėžio gydymui
LT2303021T (lt) Junginiai, skirti vėžio gydymui
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
LT2478907T (lt) Kompozicijos vėžiui gydyti
EP2059498A4 (en) TREATMENT OF CANCER
EP2144888A4 (en) METHODS OF TREATING CANCER
PT3388111T (pt) Composto organoarsénico para o tratamento de cancro
GB0707556D0 (en) Treatment for cancer
IL226362A0 (en) compounds, and methods for treating cancer
GB0600903D0 (en) Treatment of cancer
GB0604114D0 (en) Combinations for the treatment of cancer
GB0622581D0 (en) Treatment of cancer